MedPacto, Inc. 235980

Osteosarcoma management generally relies on a multimodal treatment strategy that integrates surgery with chemotherapy and, in selected cases, radiotherapy. According to the NCCN Guidelines, commonly recommended chemotherapeutic agents include methotrexate, doxorubicin, cisplatin, and ifosfamide. For patients with relapsed, refractory, or metastatic osteosarcoma, second-line options recommended by the NCCN include high-dose ifosfamide, etoposide, regorafenib, sorafenib, radium-223 dichloride, and